Literature DB >> 16490125

Modelling the hepatitis B vaccination programme in prisons.

A J Sutton1, N J Gay, W J Edmunds, N J Andrews, V D Hope, R L Gilbert, M Piper, O N Gill.   

Abstract

A vaccination programme offering hepatitis B (HBV) vaccine at reception into prison has been introduced into selected prisons in England and Wales. Over the coming years it is anticipated this vaccination programme will be extended. A model has been developed to assess the potential impact of the programme on the vaccination coverage of prisoners, ex-prisoners, and injecting drug users (IDUs). Under a range of coverage scenarios, the model predicts the change over time in the vaccination status of new entrants to prison, current prisoners and IDUs in the community. The model predicts that at baseline in 2012 57% of the IDU population will be vaccinated with up to 72% being vaccinated depending on the vaccination scenario implemented. These results are sensitive to the size of the IDU population in England and Wales and the average time served by an IDU during each prison visit. IDUs that do not receive HBV vaccine in the community are at increased risk from HBV infection. The HBV vaccination programme in prisons is an effective way of vaccinating this hard-to-reach population although vaccination coverage on prison reception must be increased to achieve this.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16490125      PMCID: PMC2870404          DOI: 10.1017/S0950268805005182

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  4 in total

1.  Injecting drug users in Edinburgh have a high rate of recidivism.

Authors:  S R Seaman; S M Gore; R P Brettle
Journal:  Addiction       Date:  2000-05       Impact factor: 6.526

2.  Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey.

Authors:  A R Weild; O N Gill; D Bennett; S J Livingstone; J V Parry; L Curran
Journal:  Commun Dis Public Health       Date:  2000-06

3.  Drug use and initiation in prison: results from a national prison survey in England and Wales.

Authors:  A Boys; M Farrell; P Bebbington; T Brugha; J Coid; R Jenkins; G Lewis; J Marsden; H Meltzer; N Singleton; C Taylor
Journal:  Addiction       Date:  2002-12       Impact factor: 6.526

4.  Hepatitis B vaccination: how to reach risk groups.

Authors:  Guido François; Johannes Hallauer; Pierre Van Damme
Journal:  Vaccine       Date:  2002-11-22       Impact factor: 3.641

  4 in total
  4 in total

1.  Modelling alternative strategies for delivering hepatitis B vaccine in prisons: the impact on the vaccination coverage of the injecting drug user population.

Authors:  A J Sutton; N J Gay; W J Edmunds; O N Gill
Journal:  Epidemiol Infect       Date:  2008-03-17       Impact factor: 2.451

2.  Estimating the variability in the risk of infection for hepatitis C in the Glasgow injecting drug user population.

Authors:  A J Sutton; S A McDonald; N Palmateer; A Taylor; S J Hutchinson
Journal:  Epidemiol Infect       Date:  2012-03-30       Impact factor: 4.434

3.  Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison.

Authors:  Andrew J Sutton; W John Edmunds; O Noel Gill
Journal:  BMC Public Health       Date:  2006-06-27       Impact factor: 3.295

4.  Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons.

Authors:  Natasha K Martin; Matthew Hickman; Alec Miners; Sharon J Hutchinson; Avril Taylor; Peter Vickerman
Journal:  BMJ Open       Date:  2013-08-13       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.